Incyte Corp reported a strong Q2 2026 performance with revenue growth led by its flagship JAKAFI franchise, which remains the core revenue driver despite its anticipated patent expiration in 2028. The company’s business model leverages specialty pharmacy distribution, extensive R&D investment focused on lifecycle management, and strategic collaborations with Novartis and Eli Lilly to extend global product reach. Industry headwinds include increasing generic filings challenging JAKAFI’s exclusivity, pricing pressures from payors, and regulatory scrutiny typical of the biopharmaceutical sector. Ongoing pipeline advancement and commercial expansion into new indications serve as critical growth levers to offset the patent cliff risk. Financially, Incyte maintains healthy liquidity but operates with elevated net debt reflecting past acquisitions and R&D commitments.